Lite Strategy, Inc. Payments of Stock Issuance Costs
Lite Strategy, Inc. (LITS) reported Payments of Stock Issuance Costs of $0 for the 12-month period ending 2023-06-30, per its 10-K filed 2023-09-26.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2023-09-26
- Lite Strategy, Inc. payments of stock issuance costs for the quarter ending 2023-06-30 was $0.00.
- Lite Strategy, Inc. payments of stock issuance costs for the quarter ending 2023-03-31 was $0.00.
- Lite Strategy, Inc. payments of stock issuance costs for the quarter ending 2022-06-30 was -$20.00K.
- Lite Strategy, Inc. payments of stock issuance costs for the quarter ending 2022-03-31 was $0.00.
- Lite Strategy, Inc. payments of stock issuance costs for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Lite Strategy, Inc. payments of stock issuance costs for fiscal 2022 was $3.65M, a 5606.25% increase from fiscal 2021.
- Lite Strategy, Inc. payments of stock issuance costs for fiscal 2021 was $64.00K, a 98.28% decline from fiscal 2020.
- Lite Strategy, Inc. payments of stock issuance costs for fiscal 2020 was $3.73M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2023-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-26 | $0.00 derived: sum of 2 quarters · filed 2023-09-26 | $0.00 10-K · filed 2023-09-26 | |
| 2023-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | $0.00 10-Q · filed 2023-05-11 | ||
| 2022-12-31 | $0.00 10-Q · filed 2023-02-09 | |||
| 2022-06-30 | -$20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-26 | -$20.00K derived: sum of 2 quarters · filed 2023-09-26 | $3.65M 10-K · filed 2023-09-26 | |
| 2022-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | $3.67M 10-Q · filed 2023-05-11 | ||
| 2021-12-31 | $3.67M 10-Q · filed 2023-02-09 | |||
| 2021-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-08 | $0.00 derived: sum of 2 quarters · filed 2022-09-08 | $64.00K 10-K · filed 2022-09-08 | |
| 2021-03-31 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2022-05-23 | $64.00K 10-Q · filed 2022-05-23 | ||
| 2020-12-31 | $64.00K 10-Q/A · filed 2022-05-23 | |||
| 2020-06-30 | $3.73M 10-K · filed 2022-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |